Your browser doesn't support javascript.
Chimeric Antigen Receptor T Cell Therapy During the COVID-19 Pandemic.
Bachanova, Veronika; Bishop, Michael R; Dahi, Parastoo; Dholaria, Bhagirathbhai; Grupp, Stephan A; Hayes-Lattin, Brandon; Janakiram, Murali; Maziarz, Richard T; McGuirk, Joseph P; Nastoupil, Loretta J; Oluwole, Olalekan O; Perales, Miguel-Angel; Porter, David L; Riedell, Peter A.
  • Bachanova V; Division of Hematology, Oncology, and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN.
  • Bishop MR; Hematopoietic Cellular Therapy Program, Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL.
  • Dahi P; Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY; Department of Medicine, Weill Cornell Medical College, New York, NY.
  • Dholaria B; Division of Hematology Oncology, Department of Medicine, Vanderbilt School of Medicine, Nashville, TN.
  • Grupp SA; Section of Cellular Therapy and Transplant, Children's Hospital of Philadelphia and Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA.
  • Hayes-Lattin B; Knight Cancer Institute, Oregon Health & Science University, Portland, OR.
  • Janakiram M; Division of Hematology, Oncology, and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN.
  • Maziarz RT; Knight Cancer Institute, Oregon Health & Science University, Portland, OR.
  • McGuirk JP; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Westwood, KS.
  • Nastoupil LJ; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Oluwole OO; Division of Hematology Oncology, Department of Medicine, Vanderbilt School of Medicine, Nashville, TN.
  • Perales MA; Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY; Department of Medicine, Weill Cornell Medical College, New York, NY.
  • Porter DL; University of Pennsylvania and Abramson Cancer Center, Philadelphia, PA. Electronic address: david.porter@pennmedicine.upenn.edu.
  • Riedell PA; Hematopoietic Cellular Therapy Program, Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL. Electronic address: priedell@medicine.bsd.uchicago.edu.
Biol Blood Marrow Transplant ; 26(7): 1239-1246, 2020 07.
Article in English | MEDLINE | ID: covidwho-100212
ABSTRACT
The SARS-CoV-2 coronavirus (COVID-19) pandemic has significantly impacted the delivery of cellular therapeutics, including chimeric antigen receptor (CAR) T cells. This impact has extended beyond patient care to include logistics, administration, and distribution of increasingly limited health care resources. Based on the collective experience of the CAR T-cell Consortium investigators, we review and address several questions and concerns regarding cellular therapy administration in the setting of COVID-19 and make general recommendations to address these issues. Specifically, we address (1) necessary resources for safe administration of cell therapies; (2) determinants of cell therapy utilization; (3) selection among patients with B cell non-Hodgkin lymphomas and B cell acute lymphoblastic leukemia; (4) supportive measures during cell therapy administration; (5) use and prioritization of tocilizumab; and (6) collaborative care with referring physicians. These recommendations were carefully formulated with the understanding that resource allocation is of the utmost importance, and that the decision to proceed with CAR T cell therapy will require extensive discussion of potential risks and benefits. Although these recommendations are fluid, at this time it is our opinion that the COVID-19 pandemic should not serve as reason to defer CAR T cell therapy for patients truly in need of a potentially curative therapy.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / T-Lymphocytes / Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / Immunotherapy, Adoptive / Lymphoma, B-Cell / Coronavirus Infections / Pandemics Type of study: Observational study / Prognostic study / Qualitative research Limits: Humans Country/Region as subject: North America Language: English Journal: Biol Blood Marrow Transplant Journal subject: Hematology / Transplantation Year: 2020 Document Type: Article Affiliation country: J.bbmt.2020.04.008

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / T-Lymphocytes / Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / Immunotherapy, Adoptive / Lymphoma, B-Cell / Coronavirus Infections / Pandemics Type of study: Observational study / Prognostic study / Qualitative research Limits: Humans Country/Region as subject: North America Language: English Journal: Biol Blood Marrow Transplant Journal subject: Hematology / Transplantation Year: 2020 Document Type: Article Affiliation country: J.bbmt.2020.04.008